Exploring CCL18, eczema severity and atopy
Article first published online: 4 MAY 2011
© 2011 John Wiley & Sons A/S
Pediatric Allergy and Immunology
Volume 22, Issue 7, pages 704–707, November 2011
How to Cite
Hon, K. L., Ching, G. K., Ng, P. C. and Leung, T. F. (2011), Exploring CCL18, eczema severity and atopy. Pediatric Allergy and Immunology, 22: 704–707. doi: 10.1111/j.1399-3038.2011.01174.x
- Issue published online: 22 SEP 2011
- Article first published online: 4 MAY 2011
- Accepted for publication 20 February 2010
- Atopic dermatitis;
To cite this article: Hon KL, Ching GK, Ng PC, Leung TF. Exploring CCL18, eczema severity and atopy. Pediatric Allergy Immunology 2011; 22: 704–707.
Background: Childhood atopic dermatitis (AD) is a distressing disease associated with pruritus, sleep disturbance, and impaired quality of life. The pathophysiology of AD is complex, and the chemokine CCL18/pulmonary and activation-regulated chemokine (PARC) may be involved.
Objective: To evaluate whether CCL18 was associated with disease severity, quality of life, nocturnal scratching, serum eosinophil, and IgE levels.
Patients and methods: Patients with AD aged 20 yr or younger were recruited. Disease severity was assessed with the SCORing Atopic Dermatitis (SCORAD) index, quality of life with the Children’s Dermatology Life Quality Index (CDLQI), and nocturnal scratching with a wrist motion monitor. Concentrations of plasma CCL18/PARC, serum total IgE, and eosinophil counts were measured in these patients.
Results: One hundred and eight patients with AD (mean [s.d.] age of 10.5 [4.4] yr) were recruited. The mean (s.d.) plasma concentration of CCL18/PARC was 162.2 (129.0) pg/ml, respectively. CCL18/PARC was significantly correlated with objective SCORAD (r = 0.44, p < 0.001), extent (r = 0.45, p < 0.001), intensity (r = 0.43, p < 0.001), the symptoms of pruritus (r = 0.20, p = 0.04), and sleep loss (r = 0.19, p = 0.049) but not with CDLQI or nocturnal scratching activities. CCL18/PARC levels were also correlated with eosinophil counts (r = 0.37, p < 0.001) and IgElog (r = 0.27, p = 0.005). Positive correlation with SCORAD was present even in patients without bronchial hyper-reactivity.
Conclusions: Serum levels of CCL18 correlate with the clinical severity score, serum eosinophil, and IgE levels. CCL18 is associated with AD and atopy.